Lewis E. Foxhall

Lewis E. Foxhall

Auto-generated profile, based on publicly available information

Lewis E. Foxhall

Health Services Research Health Services Research Health Policy Of of Chief Medical Executive in Cancer Prevention The University of Texas MD Anderson Cancer Center Houston TX

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2025 in Journal of Cancer Policy
Verified
Journal Article
Open access
LELinsey Eldridge
Linsey Eldridge
MCMishka Kohli Cira
Mishka Kohli Cira
KDKalina Duncan
Kalina Duncan
LGLeslie Given
Leslie Given
LFLewis Foxhall
Lewis Foxhall
KHKarin Hohman
Karin Hohman
The International Cancer Control Partnership (ICCP) ECHO uses a technology-enabled learning model for knowledge exchange on National Cancer Control Plans (NCCP) implementation strategies for low- and middle-income countries. We evaluated the use of this platform to bring together Ministry of Health-led, transdisciplinary teams in monthly, one-hour sessions with experts and peer presentations between 2020 and 2023. A pre-post mixed-methods design was used. Baseline and endpoint surveys (41/90, 46 %) measured changes in self-reported knowledge and confidence related to 12 strategies for NCCP implementation based on a four-point Likert scale. Comparisons were done using a paired T-test. Seven post-focus group discussions (FGDs) (6/12 countries, 50 %) captured the perceived utility of ECHO for implementing NCCP priorities. FGDs were audio-recorded, transcribed, double-coded, and underwent thematic analysis. Respondents reported high satisfaction with the curriculum, presentations, and format of the program; however, internet connectivity was a challenge, and duration was identified as an area for improvement. Average self-reported knowledge of and confidence using all 12 strategies increased significantly between pre- and post-surveys (p < 0.0001). Along with expert presentation, the peer-to-peer learning through case-based discussion enhanced their learning experience and ensured that the content was relevant. Some participants recommended incorporating additional one-on-one technical assistance during the program. Study findings suggest this interactive, bidirectional knowledge exchange approach can be effective for improving knowledge and capacity for non-clinical, system-focused areas such as cancer control planning and policy implementation. Further study is warranted to understand how cancer planners utilize their learnings.

11 January 2024 in Cancer Prevention Research
Verified
Journal Article
Closed access
PDF file
PRPaul J. Resong
Paul J. Resong
JNJiangong Niu
Jiangong Niu
GDGabrielle F. Duhon
Gabrielle F. Duhon
LFLewis E. Foxhall
Lewis E. Foxhall
SSSanjay Shete
Sanjay Shete
ITIakovos Toumazis
Iakovos Toumazis
Current lung cancer screening (LCS) guidelines rely on age and smoking history. Despite its benefit, only 5%–15% of eligible patients receive LCS. Personalized screening strategies select individuals based on their lung cancer risk and may increase LCS's effectiveness. We assess current LCS practices and the acceptability of personalized LCS among primary care providers (PCP) in Texas. We surveyed 32,983 Texas-based PCPs on an existing network (Protocol 2019-1257; PI: Dr. Shete) and 300 attendees of the 2022 Texas Academy of Family Physicians (TAFP) conference. We analyzed the responses by subgroups of interest. Using nonparametric bootstrap, we derived an enriched dataset to develop logistic regression models to understand current LCS practices and acceptability of personalized LCS. Response rates were 0.3% (n = 91) and 15% (n = 60) for the 2019–1257 and TAFP surveys, respectively. Most (84%) respondents regularly assess LCS in their practice. Half of the respondents were interested in adopting personalized LCS. The majority (66%) of respondents expressed concerns regarding time availability with the personalized LCS. Most respondents would use biomarkers as an adjunct to assess eligibility (58%), or to help guide indeterminate clinical findings (63%). There is a need to enhance the engagement of Texas-based PCPs in LCS. Most of the respondents expressed interest in personalized LCS. Time availability was the main concern related to personalized LCS. Findings from this project highlight the need for better education of Texas-based PCPs on the benefits of LCS, and the development of efficient decision tools to ensure successful implementation of personalized LCS. Prevention Relevance: Personalized LCS facilitated by a risk model and/or a biomarker test is proposed as an alternative to existing programs. Acceptability of personalized approach among PCPs is unknown. The goal of this study is to assess the acceptability of personalized LCS among PCPs.

2 February 2024
Verified
Other
Open access
PRPaul J. Resong
Paul J. Resong
JNJiangong Niu
Jiangong Niu
GDGabrielle F. Duhon
Gabrielle F. Duhon
LFLewis E. Foxhall
Lewis E. Foxhall
SSSanjay Shete
Sanjay Shete
ITIakovos Toumazis
Iakovos Toumazis
Current lung cancer screening (LCS) guidelines rely on age and smoking history. Despite its benefit, only 5%–15% of eligible patients receive LCS. Personalized screening strategies select individuals based on their lung cancer risk and may increase LCS's effectiveness. We assess current LCS practices and the acceptability of personalized LCS among primary care providers (PCP) in Texas. We surveyed 32,983 Texas-based PCPs on an existing network (Protocol 2019-1257; PI: Dr. Shete) and 300 attendees of the 2022 Texas Academy of Family Physicians (TAFP) conference. We analyzed the responses by subgroups of interest. Using nonparametric bootstrap, we derived an enriched dataset to develop logistic regression models to understand current LCS practices and acceptability of personalized LCS. Response rates were 0.3% (n = 91) and 15% (n = 60) for the 2019–1257 and TAFP surveys, respectively. Most (84%) respondents regularly assess LCS in their practice. Half of the respondents were interested in adopting personalized LCS. The majority (66%) of respondents expressed concerns regarding time availability with the personalized LCS. Most respondents would use biomarkers as an adjunct to assess eligibility (58%), or to help guide indeterminate clinical findings (63%). There is a need to enhance the engagement of Texas-based PCPs in LCS. Most of the respondents expressed interest in personalized LCS. Time availability was the main concern related to personalized LCS. Findings from this project highlight the need for better education of Texas-based PCPs on the benefits of LCS, and the development of efficient decision tools to ensure successful implementation of personalized LCS.Prevention Relevance:Personalized LCS facilitated by a risk model and/or a biomarker test is proposed as an alternative to existing programs. Acceptability of personalized approach among PCPs is unknown. The goal of this study is to assess the acceptability of personalized LCS among PCPs.

2 February 2024
Verified
Other
Open access
PRPaul J. Resong
Paul J. Resong
JNJiangong Niu
Jiangong Niu
GDGabrielle F. Duhon
Gabrielle F. Duhon
LFLewis E. Foxhall
Lewis E. Foxhall
SSSanjay Shete
Sanjay Shete
ITIakovos Toumazis
Iakovos Toumazis
Supplemental Table 2 shows a logistic regression analysis investigating various provider characteristics (age, gender, race, profession, years in practice, patients per week, work in a residency training site, work setting) as they influence responses to the question of whether or not providers recommend lung cancer screening for eligible patients.

2 February 2024
Verified
Other
Open access
PRPaul J. Resong
Paul J. Resong
JNJiangong Niu
Jiangong Niu
GDGabrielle F. Duhon
Gabrielle F. Duhon
LFLewis E. Foxhall
Lewis E. Foxhall
SSSanjay Shete
Sanjay Shete
ITIakovos Toumazis
Iakovos Toumazis
Supplemental Table 4 shows provider level of agreement between 3 different proposed uses of biomarkers for lung cancer screening: as an adjuvant to the current screening, as a standalone means of screening, or as a guide to uncertain findings to the current screening methods.

2 February 2024
Verified
Other
Open access
PRPaul J. Resong
Paul J. Resong
JNJiangong Niu
Jiangong Niu
GDGabrielle F. Duhon
Gabrielle F. Duhon
LFLewis E. Foxhall
Lewis E. Foxhall
SSSanjay Shete
Sanjay Shete
ITIakovos Toumazis
Iakovos Toumazis
Supplemental Table 4 shows provider level of agreement between 3 different proposed uses of biomarkers for lung cancer screening: as an adjuvant to the current screening, as a standalone means of screening, or as a guide to uncertain findings to the current screening methods.